Kuria Therapeutics, a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic disease, will be holding meetings with investors and other parties during the 44th Annual J.P. Morgan Healthcare Conference, January 11-15 2026, in San Francisco, California. Kuria's Chief Executive Officer, Dr. Keith Ward, will be holding one-on-one meetings during the conference to discuss the latest company and data updates for Kuria's lead program transforming treatm

Kuria granted an SBIR award to fund IND-enabling toxicology studies for Fuchs' dystrophy.

- Kuria to present positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and retina disease Kuria...

- Kuria team to present potency, selectivity, and positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and...

- Kuria's Chief Executive Officer Dr. Keith Ward to present company overview to premiere venture forum in the Southeast Kuria...

- Kuria's Chief Executive Officer and Chief Development Officer to share ophthalmic program updates and present corporate overview Kuria...

- Chief Development Officer Dave Flory to present corporate overview and review Kuria's development plans for diseases of the cornea and...

- Expands development pipeline with planned Phase 2 clinical trial for dry AMD Kuria Therapeutics, a pharmaceutical company developing a...

Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease LITTLE ROCK,...

SCOHIA PHARMA and Kuria Therapeutics Announce Issuance of Key Patent Covering Novel Nrf2 Activator KANAGAWA, Japan & LITTLE ROCK,...

Kuria Therapeutics Closes Initial Fundraising Round to Develop Novel Nrf2 Activator - Funds to support ongoing preclinical development...

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2...